S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:PRPO - Precipio Stock Price, Forecast & News

$2.09
-0.05 (-2.34 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$2.00
Now: $2.09
$2.12
50-Day Range
$1.81
MA: $2.01
$2.25
52-Week Range
$1.65
Now: $2.09
$10.80
Volume224,100 shs
Average Volume281,500 shs
Market Capitalization$16.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Precipio, Inc, a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRPO
CUSIPN/A
Phone203-787-7888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.86 million
Book Value$2.66 per share

Profitability

Net Income$-15,690,000.00
Net Margins-525.32%

Miscellaneous

Employees42
Market Cap$16.76 million
Next Earnings Date4/21/2020 (Estimated)
OptionableNot Optionable

Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.


Brand NEW way to make money -- previously reserved for the financial elite (Ad)


Former Lehman Brothers executive reveals one of Wall Street's best kept secrets. A proven system for turning $1,000 into $1.3 Million (or more) - without touching the stock market.

In fact, this system is responsible for the most profitable investment of all time!

Precipio (NASDAQ:PRPO) Frequently Asked Questions

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

When did Precipio's stock split? How did Precipio's stock split work?

Precipio shares reverse split on the morning of Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

How were Precipio's earnings last quarter?

Precipio (NASDAQ:PRPO) released its earnings results on Wednesday, November, 13th. The biotechnology company reported ($0.31) EPS for the quarter. The biotechnology company earned $0.78 million during the quarter. Precipio had a negative return on equity of 94.75% and a negative net margin of 525.32%. View Precipio's Earnings History.

When is Precipio's next earnings date?

Precipio is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Precipio.

What price target have analysts set for PRPO?

1 analysts have issued 1-year price targets for Precipio's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Precipio's stock price to reach $4.00 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View Analyst Price Targets for Precipio.

What is the consensus analysts' recommendation for Precipio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Precipio.

Has Precipio been receiving favorable news coverage?

News headlines about PRPO stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Precipio earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Precipio.

Who are some of Precipio's key competitors?

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Portola Pharmaceuticals (PTLA), Biocept (BIOC), MannKind (MNKD), Jaguar Health (JAGX), Inpixon (INPX), TrovaGene (TROV), ACADIA Pharmaceuticals (ACAD), AEterna Zentaris (AEZS), Avid Bioservices (CDMO) and Cellectar Biosciences (CLRB).

Who are Precipio's key executives?

Precipio's management team includes the folowing people:
  • Mr. Ilan Danieli, Founder, Pres, CEO & Director (Age 47)
  • Mr. Carl R. Iberger, CFO & Sec. (Age 66)
  • Mr. Ahmed Zaki Sabet, Chief Operating Officer (Age 33)
  • Mr. Douglas Sites, VP of Sales
  • Mr. Ayman Mohamed, Sr. VP of R&D and Laboratory Operations (Age 34)

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $2.09.

How big of a company is Precipio?

Precipio has a market capitalization of $16.76 million and generates $2.86 million in revenue each year. Precipio employs 42 workers across the globe.View Additional Information About Precipio.

What is Precipio's official website?

The official website for Precipio is http://www.precipiodx.com/.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]


MarketBeat Community Rating for Precipio (NASDAQ PRPO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Precipio and other stocks. Vote "Outperform" if you believe PRPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel